inotropikler

Inotropikers are a class of cardiovascular drugs that are used to increase the force of cardiac contractions and improve cardiac function. They are often used in patients with heart failure, cardiogenic shock, or other conditions that impair the heart's ability to pump blood effectively.

Inotropikers work by increasing the concentration of calcium ions within the cardiac muscle cells, which in turn increases the contractile force of the heart. This has the effect of increasing cardiac output, improving cardiac efficiency, and reducing symptoms of heart failure.

There are three main types of inotropikers: beta-1 agonists, phosphodiesterase inhibitors, and calcium sensitizers. Beta-1 agonists, such as dobutamine, work by stimulating the beta-1 receptors in the heart, leading to increased calcium availability and increased contractility. Phosphodiesterase inhibitors, such as milrinone, work by increasing the levels of cyclic adenosine monophosphate (cAMP) in the heart, leading to increased contractility and relaxation. Calcium sensitizers, such as levosimendan, work by increasing the sensitivity of the cardiac muscle to calcium without increasing its availability.

Inotropikers are typically used in hospitalized patients who require close monitoring due to their potential side effects, such as tachycardia, hypertension, and arrhythmias. They are also used in patients who are not responding to conventional treatments for heart failure, such as diuretics and ACE inhibitors.